Related Experiment Video
Updated: Jan 15, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Effectiveness of First-Line Empirical Treatment in Portugal: Data from the European Registry on Helicobacter pylori
Maria Inês Viegas1, Miguel Areia1,2, Luís Elvas1
1Gastroenterology Department, Portuguese Oncology Institute of Coimbra (IPO Coimbra), Coimbra, Portugal.
Introduction:
As Portugal exhibits some of the highest gastric cancer rates in Europe, optimizing the Helicobacter pylori eradication rate is imperative. We aimed to describe H. pylori treatment regimens in Portugal, within a real clinical practice setting.
Methods:
This is a prospective cohort study of the Portuguese patients diagnosed with H. pylori between May 2013 and December 2022, within the European Registry on Helicobacter pylori Management (Hp-EuReg). The demographic and clinical data, diagnostic methods, treatment regimens, and prescription trends with their effectiveness were analysed by modified intention-to-treat (mITT) and per-protocol (PP) analyses.
Results:
Overall, 700 cases, mainly from 2 centres (98% of cases), were included, with 59% females, with a mean age of 54 ± 15 years. Treatment-naïve patients encompassed 81% of cases. Overall compliance (>90% drug intake) was reported in 99% of cases. Overall effectiveness was 87%, by both mITT and PP analyses. The triple PPI-clarithromycin-amoxicillin therapy decreased from 29% in 2013 to 0% in 2022. Conversely, both quadruple concomitant PPI-clarithromycin-amoxicillin-metronidazole and PPI-bismuth-metronidazole-tetracycline therapies were predominantly used from 2016 onwards, with PPI-bismuth-metronidazole-tetracycline representing 76% of all prescriptions in 2022, achieving an overall mITT effectiveness of 92% and 91%, respectively.
Conclusion:
In Portugal, concomitant quadruple therapy with PPI-clarithromycin-amoxicillin-metronidazole and bismuth quadruple with PPI-bismuth-metronidazole-tetracycline provided both optimal (>90%) effectiveness, in line with results of other Southern European countries.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...